Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Sanofi Pasteur Inc
Woman and Man Max 99 years
Sanofi Pasteur Inc
Update Il y a 4 ans
Reactogenicity of Acellular Pertussis Vaccine Booster in Adolescents Who Have Received 5 Prior Doses Of BIKEN Acellular Pertussis Vaccine in Combination with Diphtheria and Tetanus Toxoids (Tripedia®) Or Who Have Received Primary Vaccination with 3 Doses of Whole-Cell Pertussis Vaccine, Plus At Least 1 Pertussis Booster Vaccination
To describe and characterize adverse events occurring after vaccination with COVAXiS or REPEVAX vaccine among two groups: Group 1 - adolescents 10-14 years of age who participated in study 371-03/01 ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Sanofi Pasteur Incorporated
Update Il y a 4 ans
A randomised, controlled, double blind study of the immunogenicity and safety of PEDIACEL®, a combined diphtheria, tetanus, five component acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate vaccine (adsorbed) compared to Infanrix™–IPV+Hib when both vaccines are given to infants using a three dose immunisation schedule (“Nordic schedule” 3-5-12 months)
To assess the immunogenicity post-dose 3 of PEDIACEL® (Group A) and Infanrix™–IPV+Hib (Group B) when administered to infants at 3, 5 and 12 months of age.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi Pasteur Incorporated
Update Il y a 4 ans
Safety and Immunogenicity of Booster Vaccination with PEDIACEL®, a Combined Diphtheria, Tetanus, Five Component Acellular Pertussis, Inactivated Poliomyelitis and Haemophilus Influenzae Type b Conjugate Vaccine (Adsorbed), Compared to Booster Vaccination with Infanrix® hexa when Both Vaccines Are Co-Administered with Prevenar® to Toddlers 11-18 Months of Age
To evaluate the safety of PEDIACEL® booster dose by comparing the fever rates between PEDIACEL® and Infanrix® hexa vaccines when both are co-administered with Prevenar® to toddlers at 11-18 months of ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi Pasteur Inc
Update Il y a 4 ans
A Phase II randomized, placebo-controlled, double-blind, dose ranging study of a Clostridium difficile toxoid vaccine (ACAM-CDIFF) in subjects with Clostridium difficile-associated infection(CDI)
To compare the event rate of CDI in groups assigned to ACAM-CDIFF vaccine (pooled groups) versus placebo in the 9 week period after the third dose of study vaccine (Study Days 29 to 91) in subjects wi...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi Pasteur Inc
Update Il y a 4 ans
Comparison of Pertussis Specific Cellular and Humoral Immunity Before and After a Acellular Pertussis Booster-Vaccineation in Combination With a Diphtheria-Tetanus-Polio-Vaccine Between Three Groups of Adolescents 10-14 Years of Age That Have Previously Either Received 4 or 5 Doses of Acellular Pertussis Vaccine or 4 Doses of of Whole-Cell Pertussis Vaccine
Evaluation of the pertussis-specific humoral and cellular immunity after vaccination with REPEVAX® or COVAXiS® or COVAXiS® + IPV Merieux® among three groups: Group A: Adolescents 10-14 years of age w...
Country
None
organs
None
Specialty
None
Closed trial
More information